Dr. Charles Y. Lin, Ph.D., joined Kronos Bio in December 2019, and serves as Senior Vice President, Research and Development, where he has primary responsibility for the company’s discovery and scientific functions, including the company’s proprietary product engine and innovative translational science.

Before his tenure at Kronos Bio, Charles earned distinction as a Pew-Stewart Scholar for Cancer Research and served as an Assistant Professor in the Department of Molecular and Human Genetics at the Baylor College of Medicine. There, he also co-directed the Therapeutic Innovation Center, leading groundbreaking research that has reshaped the understanding of gene control mechanisms in cancer.

Charles’ pioneering work on the MYC transcription factor, the most commonly amplified human oncogene and his insights into super enhancers, control regions of the genome that activate oncogenes, have advanced the development of a number of novel small-molecule inhibitors of transcription.

Charles received his Ph.D. in Computational and Systems Biology from the Massachusetts Institute of Technology, where he trained with Dr. Richard Young and Dr. Christopher Burge. He completed post-doctoral work with Dr. James Bradner at the Dana-Farber Cancer Institute in the chemical biology program. As our SVP, Research and Development, Charles’ leadership in science not only accelerates the company’s mission to develop life-saving therapies, but his unique blend of computational expertise and deep biological insight continues to drive the evolution of treatment strategies.